


EXPRESS MAIL CERTIFICATE

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Typed or Printed Name	Margaret Pierce	Express Mail No.	EL 563 388 126 US
Signature		Date	February 8, 2001

PRELIMINARY AMENDMENT

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket	CONN-003CON
First Named Inventor	Elaine Unemori
Application Number	Unassigned
Filing Date	Even Date Herewith
Group Art Unit	Unassigned
Examiner Name	Unassigned
Title	METHOD OF PROMOTING ANGIOGENESIS

Sir:

This is a preliminary amendment to the patent application identified above. Prior to examination of the subject application, please enter the following amendments to the specification and claims:

AMENDMENTS

IN THE SPECIFICATION:

On page 1 beneath the title please add the following:

--Cross-Reference to Related Applications:

This application is a continuation of Application Ser. No. 08/698,359, filed August 15, 1996 of which is incorporated herein by reference and to which is claimed priority under 35 U.S.C. §120.—

At page 4, line 28, please delete --(as described in co-pending application Serial No. 08/484,219--, and insert in its place—(as described in U.S. Patent 5,911,997 at SEQ ID NOS: 3 and 4, and column 5, line 27 – column 6, line 4)—

At page 4, line 29 please delete --(as described in co-pending application Serial No. 08/483,476-- and insert in its place—(as described in U.S. Patent 5,811,395 at SEQ ID NOS: 1 and 2, and column 3, lines 16-40)—

At Page 4, line 28, after the word "Relaxin" please insert --, and portions that retain biological activity--.

At Page 4, line 29, after the word "analogs" please insert --, and portions that retain biological activity--.

08/698,359-000001

Page 6, line 22 change "treating depression" to --promoting angiogenesis--.

IN THE CLAIMS:

Please amend the claims as follows:

Cancel original claims 1-22 and add the following new claims 23-35.

23. (New) A method of treatment, comprising:

administering recombinant human relaxin (H2) to a patient at a predetermined rate so as to maintain a serum concentration of at least about 1 ng/ml;

continuing the administration over a period sufficient to obtain a therapeutic effect on the patient.

24. (New) The method of claim 23, wherein relaxin is administered from an osmotic pump.

25. (New) The method of claim 24, wherein the osmotic pump is a multi-chamber osmotic pump system.

26. (New) The method of claim 23, wherein the predetermined rate comprises sequentially timed dispensing from an osmotic pump.

27. (New) The method of claim 23, wherein the administering is at a progressively diminishing rate.

28. (New) A method of inducing secretion of vascular endothelial growth factor (VEGF), comprising the steps of:

administering recombinant human (H2) to a patient wherein the administering is in a sufficient amount and over a sufficient period of time so as to induce VEGF secretion.

29. (New) The method of claim 28, wherein the relaxin is administered at a predetermined rate so as to maintain a therapeutic serum concentration of relaxin in the patient.

30. (New) The method of claim 29, wherein the serum concentration of relaxin is at least about 1 ng/ml.

31. (New) The method of claim 30 wherein the serum concentration of relaxin is maintained for a period of up to at least 72 hours.

32. (New) The method of claim 31 wherein relaxin is administered from an osmotic pump.

33. (New) The method of claim 32, wherein the osmotic pump is a multi-chamber osmotic pump system.

34. (New) The method of claim 29, wherein the predetermined rate comprises sequentially timed dispensing from an osmotic pump.

35. (New) The method of claim 28, wherein the administering is at a progressively diminishing rate.

REMARKS

Claims 23-35 are now pending in this application.

Original claims 1-22 have been canceled and new claims 23-35 have been added to more particularly point out and distinctly claim the invention. No new matter has been added.

New claims 23-27 correspond largely to allowed claims 28-32 within the parent application Serial No. 08/698,359 which claims have been allowed. New claim 23 is directed to a method of treatment as opposed to the specific method of promoting angiogenesis claimed within allowed claim 28 of the parent application. The dependent claims 24-27 are identical to the allowed claims 29-32 except for the numbering and their being dependent on different claims.

New claims 28-35 are supported within the originally filed application such as within Example 3 on pages 10-11 of the original specification. Example 3 clearly shows that recombinant human relaxin can be administered over time in a manner so as to induce secretion of vascular endothelial growth factor (VEGF). The specific number limitations within claims 30 and 31 are supported in the specification at page 11, lines 4 and 6 respectively. Dependent claims 32-35 are identical to allowed claims 29-32 of the parent application except for the numbering and the fact that these claims are dependent on different claims. No new matter has been added.

In the event any fees are due in connection with the filing of this preliminary amendment or attached application or if petitions are required, applicants petition for any required relief and authorize the Commissioner to charge the cost of such petitions or other fees to our Deposit Account No. 50-0815.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

Feb 8, 2001

By:

Karl Bozicevic
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, California 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231
F:\DOCUMENT\CONN\003con\Amendment - Preliminary.rtf